FSC and CPP: China Export Documents for APIs, Explained

Commercial documents describe the shipment. Regulatory documents describe the trade. A free sale certificate and a certificate of a pharmaceutical product belong to the second kind, and buyers who first meet them at a port of entry usually meet them without enough time to fix anything.

This piece maps the two documents, who issues them, what each attests, and where each one sits in an order timeline. It deliberately stays at the level of structure rather than jurisdiction-specific detail, because the receiving country's rules decide which of the two you actually need.

The free sale certificate

An FSC, sometimes called a certificate of free sale, is an authority statement that a product is lawfully marketed in the exporting country. It says nothing about your batch, your supplier's quality system or the substance's dossier; it attests marketability. Importing authorities request it where they need evidence that the goods are not leaving the exporting country through a back door.

Two properties matter to a buyer. First, the FSC is issued about a product and a legal entity, so names and addresses must match the trade documents exactly; a mismatch between the certificate and the invoice is the classic clearance delay, and the general discipline is the same as that in shipment document consistency. Second, the issuing authority matters more than the paper: a certificate from the authority that actually regulates the product category carries weight that a chamber-of-commerce attestation does not.

The certificate of a pharmaceutical product

The CPP is a different instrument with a longer pedigree. Under the WHO scheme, the exporting authority certifies what product authorisations exist in the exporting country for a named product made by a named holder at a named site, and it lists the status of those authorisations. The importing authority uses it as the trusted basis for its own registration or import decision.

The crucial reading point: a CPP is a statement about authorisations, not about quality. It does not attest that a batch is good; it attests that a regulatory relationship exists for the product and site named on it. That is why site and holder lines are not bureaucratic decoration; they are the substance of the document. Where your dossier references a manufacturing site, the CPP's site line and your dossier must agree, in the same way a CEP's holder and site lines must agree with the certificate actually held, as covered in certificate verification.

Timeline: where each document is earned

Neither document is produced at the port; both are produced by a request chain that starts weeks earlier. The sequence that works is short. At contract stage, ask the importing side exactly which documents it requires, in which language, legalised or not. At production stage, request the certificates with product, entity and site names finalised, because corrections cycle slowly through authorities. At shipment stage, check the set against the commercial pack so that every name, address and product description agrees line by line; the full pack for a first order is itemised in the first-order document pack.

Legalisation, where required, is the other slow-motion step: notarisation, authority endorsement and consular legalisation each take their own calendar. Building those weeks into the plan costs nothing; discovering the requirement at the port costs the shipment's schedule, and sometimes its shelf life.

What the two documents are not

Neither document is a quality statement, and neither substitutes for the pharmacopoeial and dossier instruments that market access usually requires; the map of those instruments is in the CEP, DMF and written confirmation comparison. And neither travels instead of the batch documents; it travels with them, and the customs side of the journey is its own discipline, covered in HS classification for bile acid products.

The takeaway is timing, not paperwork volume. Both documents are cheap when requested early and expensive when requested late, and the only decision a buyer must make is to ask the importing authority's question first.

Jurisdictions differ in which of the two documents they actually request, and the difference follows the receiving authority's own framework. Authorities operating registration systems keyed to the WHO scheme tend to want the CPP; authorities screening for lawful commercial channels tend to want the free sale certificate; some want both, and some want neither and work entirely from the dossier instruments. Asking the importing side's question first is the whole planning step, and the WHO certification framework is the reference point from which most national variants derive.

Language and legalisation deserve their own line in the plan. Many authorities require certificates in their own language or in English, and legalisation chains, notarisation, competent-authority endorsement, consular steps, run on government calendars that do not compress. Where legalisation is required, the total lead time is measured in weeks even when the issuing authority itself is fast, and the buyer who books those weeks at contract stage pays nothing for them.

Failure modes cluster predictably. Product descriptions on the certificate that differ from the invoice's wording, so that a customs officer cannot tell they are the same goods. Entity names updated after a corporate change but not across the document set. Site names on the CPP that disagree with the manufacturing site the dossier claims. Each is trivial to fix before shipment and expensive after, and the reconciliation habit that catches them is the same line-by-line discipline described in shipment document consistency.

For buyers building the full first-order pack, these two documents slot into the regulatory layer alongside whatever the market route requires; the assembly is itemised in the first-order document pack, and the customs layer of the journey, where classification and valuation live, is treated separately in HS classification. Trade-practice references worth keeping at hand include the World Customs Organization and the International Trade Centre, both of which publish guidance on cross-border document sets.

The documents are simple. The discipline that makes them work is asking early, naming exactly, and reconciling line by line before anyone else reads the set.

Frequently asked questions

What is a free sale certificate?

An authority statement that a product is lawfully marketed in the exporting country. It attests marketability, not batch quality, and must match the names and addresses on the trade documents exactly to avoid clearance delays.

How does a CPP differ from an FSC?

A CPP certifies the status of product authorisations in the exporting country for a named product, holder and site, under the WHO scheme, and serves as the basis for another authority's registration decision. An FSC merely attests lawful marketing. The CPP is the heavier regulatory instrument.

Does a CPP say anything about batch quality?

No. It is a statement about authorisations, not about quality. Batch quality is attested by the COA, the release process and the dossier instruments, which is why site and holder lines on the CPP matter so much: they tie the authorisation to your actual supply chain.

When should I request these documents?

Confirm requirements with the importing side at contract stage, request certificates with finalised names at production stage, and reconcile the full set against commercial documents before shipment. Legalisation steps, where required, add weeks and belong in the plan from the start.

What causes the most clearance delays with these documents?

Name, address or product description mismatches between the certificates and the invoice or packing list, and missing legalisation discovered at the port. Both are preventable with a line-by-line reconciliation before shipment.

Can these documents replace COAs or CEPs?

No. They travel alongside batch and dossier documents, each answering a different question: marketability, authorisation status, batch results and dossier assessment. None of them substitutes for another.